Financial Performance - The company's operating revenue for Q1 2023 was RMB 349,712,760.42, representing a year-on-year increase of 31.71%[4] - Net profit attributable to shareholders was RMB 102,686,545.40, reflecting a growth of 53.71% compared to the same period last year[4] - The net profit after deducting non-recurring gains and losses was RMB 90,064,379.49, up by 49.08% year-on-year[4] - Basic earnings per share for the period were RMB 1.54, an increase of 54.00% compared to the previous year[4] - The company reported a gross profit margin of approximately 29.1% for Q1 2023, compared to 24.8% in Q1 2022[17] - The total comprehensive income attributable to the parent company's owners for Q1 2023 was ¥102,497,749.73, a significant increase of 53.5% compared to ¥66,796,970.25 in Q1 2022[19] Cash Flow - The net cash flow from operating activities reached RMB 116,347,052.18, marking a significant increase of 74.73%[4] - Cash inflow from operating activities totaled ¥424,986,539.90 in Q1 2023, up from ¥315,380,775.19 in Q1 2022, representing a 34.7% increase[20] - Cash outflow from operating activities increased to ¥308,639,487.72 in Q1 2023, compared to ¥248,793,254.26 in Q1 2022, a rise of 24%[22] - The company reported a net increase in cash and cash equivalents of ¥256,309,734.91 for Q1 2023, compared to ¥105,041,796.89 in Q1 2022, reflecting a 143% increase[22] Assets and Liabilities - Total assets at the end of the reporting period were RMB 2,382,598,153.66, a 7.04% increase from the end of the previous year[5] - The company's total assets amounted to RMB 2,382,598,153.66, an increase from RMB 2,225,978,346.27 as of December 31, 2022, reflecting a growth of approximately 7.06%[13] - The total current assets increased to RMB 1,690,030,123.98 from RMB 1,557,457,712.49, representing a growth of about 8.49%[14] - The total liabilities as of March 31, 2023, were ¥487,206,301.68, compared to ¥434,912,807.26 at the end of 2022, indicating a 12.0% rise[16] - The company's total liabilities increased, with accounts payable rising to RMB 41,849,945.07 from RMB 41,220,788.18, an increase of 1.53%[14] Research and Development - R&D investment totaled RMB 52,606,928.37, which accounted for 15.04% of operating revenue, a decrease of 1.71 percentage points[5] - Research and development expenses in Q1 2023 amounted to ¥52,606,928.37, an increase of 18.3% from ¥44,482,715.95 in Q1 2022[17] Market and Growth - The increase in sales scale and improved product profitability were key drivers for the significant profit growth[8] - The company continues to expand its market presence, particularly in overseas markets and OEM business, contributing to sustained revenue growth[8] - The company has not disclosed any significant new product developments or market expansion strategies in this quarter[12]
惠泰医疗(688617) - 2023 Q1 - 季度财报